Eijiro Ozawa

Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy

Severe childhood autosomal recessive muscular dystrophy (SCARMD) is a progressive muscle-wasting disorder common in North Africa that segregates with microsatellite markers at chromosome 13q12. Here, it is shown that a mutation in the gene encoding the 35-kilodalton dystrophin-associated glycoprotein, γ-sarcoglycan, is likely to be the primary genetic defect in this disorder. The human γ-sarcoglycan gene was mapped to chromosome 13q12, and deletions that alter its reading frame were identified in three families and one of four sporadic cases of SCARMD. These mutations not only affect γ-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex.

β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex

The dystrophin associated proteins (DAPs) are good candidates for harboring primary mutations in the genetically heterogeneous autosomal recessive muscular dystrophies (ARMD). The transmembrane components of the DAPs can be separated into the dystroglycan and the sarcoglycan complexes. Here we report the isolation of cDNAs encoding the 43 kD sarcoglycan protein β–sarcoglycan (A3b) and the localization of the human gene to chromosome 4q12. We describe a young girl with ARMD with truncating mutations on both alleles. Immunostaining of her muscle biopsy shows specific loss of the components of the sarcoglycan complex β–sarcoglycan, α–sarcoglycan (adhalin), and 35 kD sarcoglycan). Thus secondary destabilization of the sarcoglycan complex may be an important pathophysiological event in ARMD.

From dystrophinopathy to sarcoglycanopathy : Evolution of a concept of muscular dystrophy

Duchenne and Becker muscular dystrophies are collectively termed dystrophinopathy. Dystrophinopathy and severe childhood autosomal recessive muscular dystrophy (SCARMD) are clinically very similar and had not been distinguished in the early 20th century. SCARMD was first classified separately from dystrophinopathy due to differences in the mode of inheritance. Studies performed several years ago clarified some immunohistochemical and genetic characteristics of SCARMD, but many remained to be clarified. In 1994, the sarcoglycan complex was discovered among dystrophin‐associated proteins. Subsequently, on the basis of our immunohistochemical findings which indicated that all components of the sarcoglycan complex are absent in SCARMD muscles, and the previous genetic findings, we proposed that a mutation of any one of the sarcoglycan genes leads to SCARMD. This hypothesis explained and predicted various characteristics of SCARMD at the molecular level, most of which have been verified by subsequent discoveries in our own as well as various other laboratories. SCARMD is now called sarcoglycanopathy, which is caused by a defect of any one of four different sarcoglycan genes, and thus far mutations in sarcoglycan genes have been documented in the SCARMD patients. In this review, the evolution of the concept of sarcoglycanopathy separate from that of dystrophinopathy is explained by comparing studies on these diseases.

Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain

Dystrophin, a protein product of the Duchenne muscular dystrophy gene, is thought to associate with the muscle membrane by way of a glycoprotein complex which was co‐purified with dystrophin. Here, we firstly demonstrate direct biochemical evidence for association of the carboxy‐terminal region of dystrophin with the glycoprotein complex. The binding site is found to lie further inward than previously expected and confined to the cysteine‐rich domain and the first half of the carboxy‐terminal domain. Since this portion corresponds well to the region that, when missing results in severe phenotypes, our findings may provide it molecular basis of the disease.

Mutations in the sarcoglycan genes in patients with myopathy.

BACKGROUND Some patients with autosomal recessive limb-girdle muscular dystrophy have mutations in the genes coding for the sarcoglycan proteins (alpha-, beta-, gamma-, and delta-sarcoglycan). To determine the frequency of sarcoglycan-gene mutations and the relation between the clinical features and genotype, we studied several hundred patients with myopathy. METHODS Antibody against alpha-sarcoglycan was used to stain muscle-biopsy specimens from 556 patients with myopathy and normal dystrophin genes (the gene frequently deleted in X-linked muscular dystrophy). Patients whose biopsy specimens showed a deficiency of alpha-sarcoglycan on immunostaining were studied for mutations of the alpha-, beta-, and gamma-sarcoglycan genes with reverse transcription of muscle RNA, analysis involving single-strand conformation polymorphisms, and sequencing. RESULTS Levels of alpha-sarcoglycan were found to be decreased on immunostaining of muscle-biopsy specimens from 54 of the 556 patients (10 percent); in 25 of these patients no alpha-sarcoglycan was detected. Screening for sarcoglycan-gene mutations in 50 of the 54 patients revealed mutations in 29 patients (58 percent): 17 (34 percent) had mutations in the alpha-sarcoglycan gene, 8 (16 percent) in the beta-sarcoglycan gene, and 4 (8 percent) in the gamma-sarcoglycan gene. No mutations were found in 21 patients (42 percent). The prevalence of sarcoglycan-gene mutations was highest among patients with severe (Duchenne-like) muscular dystrophy that began in childhood (18 of 83 patients, or 22 percent); the prevalence among patients with proximal (limb-girdle) muscular dystrophy with a later onset was 6 percent (11 of 180 patients). CONCLUSIONS Defects in the genes coding for the sarcoglycan proteins are limited to patients with Duchenne-like and limb-girdle muscular dystrophy with normal dystrophin and occur in 11 percent of such patients.

The Three Human Syntrophin Genes Are Expressed in Diverse Tissues, Have Distinct Chromosomal Locations, and Each Bind to Dystrophin and Its Relatives

The syntrophins are a biochemically heterogeneous group of 58-kDa intracellular membrane-associated dystrophin-binding proteins. We have cloned and characterized human acidic (α1-) syntrophin and a second isoform of human basic (β2-) syntrophin. Comparison of the deduced amino acid structure of the three human isoforms of syntrophin (together with the previously reported human β1-syntrophin) demonstrates their overall similarity. The deduced amino acid sequences of human α1- and β2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms. Much like β1-syntrophin, human β2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance. In contrast, human α1-syntrophin is most abundant in heart and skeletal muscle, and less so in other tissues. Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: β2-syntrophin to chromosome 16q22-23 and α1-syntrophin to chromosome 20q11.2. Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like β1-syntrophin, both β2- and α1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.

Molecular and cell biology of the sarcoglycan complex

The original sarcoglycan (SG) complex has four subunits and comprises a subcomplex of the dystrophin–dystrophin‐associated protein complex. Each SG gene has been shown to be responsible for limb‐girdle muscular dystrophy, called sarcoglycanopathy (SGP). In this review, we detail the characteristics of the SG subunits, and the mechanism of the formation of the SG complex and various molecules associated with this complex. We discuss the molecular mechanisms of SGP based on studies mostly using SGP animal models. In addition, we describe other SG molecules, ϵ‐ and ζ‐SGs, with special reference to their expression and roles in vascular smooth muscle, which are currently in dispute. We further consider the maternally imprinted nature of the ϵ‐SG gene. Finally, we stress that the SG complex cannot work by itself and works in a larger complex system, called the transverse fixation system, which forms an array of molecules responsible for various muscular dystrophies. Muscle Nerve, 2005

A myotrophic protein from chick embryo extract: Its purification, identity to transferrin, and indispensability for avian myogenesis☆

Abstract Chick embyro extract (EE) has been widely employed as a growth-promoting supplement in avian myogenic cell cultures. We have purified a myotrophic substance from EE with ammonium sulfate precipitation, CM-Sephadex and DEAE-cellulose chromatography. Salt gradient elution from DEAE-cellulose columns yielded three active peaks with a protein of 80K daltons. The proteins have different isoelectric points of 6.1, 5.9, and 5.7, respectively. They promoted chick myoblasts to proliferate and myotubes to grow when added in the place of EE to a basal culture medium (BCM) composed of Eagles minimal essential medium and horse serum. Their myotrophic activities were the same and reversibly lost by removal of protein-bound Fe. They were identified as transferrin (Tf) species of differing numbers of sialic acid residues, on the basis of physicochemical and immunological analyses. Tf in EE consisted of species of fewer sialic acid residues than adult serum Tf. Indispensability of Fe-bound Tf for EE to exert myotrophic activity was demonstrated by experiments to remove Tf by immunoprecipitation and to remove Fe from Tf in EE. Either treatment led to a complete loss of the myotrophic activity, which was restored by supplementation of Fe-bound Tf or Fe3+. Comparison of myotrophic activity of EE with that of Tf indicated the presence of other factors in EE which promote myogenic cell growth synergistically with Tf. From the results and on the basis of the class-specific function of Tf on the cells, we discuss the relation of Tf to nerve-derived myotrophic proteins and other factors in EE.

Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects

We examined muscle biopsies from patients with Duchenne muscular dystrophy (DMD: 39 patients) and Becker muscular dystrophy (BMD: 11 patients), female DMD-carriers (4 patients), and control subjects (26 persons) for the expression of dystrophin and utrophin. Control subjects showed all fibers to be dystrophin-positive, while utrophin staining was negative or weak. On the other hand, muscles from DMD patients showed the inverse staining patterns: dystrophin was negative and utrophin staining strong. Thus, there was a reciprocal pattern of expression between dystrophin and utrophin. This reciprocal relationship was confirmed to some extent at the single-fiber level in female carriers of DMD showing a mosaic immunostaining of dystrophin. We consider that utrophin may have a function similar to that of dystrophin, and compensate to some extent for dystrophin deficiency in DMD.

Expression of a dystrophin-related protein associated with the skeletal muscle cell membrane

SummaryWe previously reported that a protein which has immunological cross-reactivity with and a molecular weight similar to dystrophin, the Duchenne muscular dystrophy (DMD) gene product, is expressed on the muscle cell membrane (Tanaka et al. 1989b). To examine if this is the translation product of the autosomal transcript with homology to dystrophin mRNA identified by Love et al. (1989), we raised an antibody (PDRP) against a synthetic peptide corresponding to the putative protein (DRP) and examined its expression and cellular localization in human and murine skeletal muscle samples. In immunoblotting, PDRP stained a band with a similar molecular weight to dystrophin in samples from DMD and Becker muscular dystrophy (BMD) patients and control (non-DMD/BMD) human. PDRP was expected not to cross-react with dystrophin because the antigenic peptide was not homologous to dystrophin. In fact, PDRP did not cross-react with dystrophin present in a BMD patient. Immunohistochemically, PDRP stained the muscle cell membrane in samples from DMB and BMD patients and from mdx mice. Only a slight staining was observed in muscles from control human and wild type mice. Our results confirm the presence of DRP in human and murine skeletal muscles, and further demonstrate that it is localized on the cell membrane. The abundance of DRP in dystrophin deficient muscles might be related to some compensatory mechanisms.